![](https://investorshub.advfn.com/uicon/564105.png?cb=1547105359)
Wednesday, June 23, 2021 2:40:39 PM
This sounds to me like an endorsement, just not one which calls out Tempol specifically yet. The NIH info over the past couple weeks certainly indicates that Tempol appears to meet this criteria, so in combination, I think the word "endorse" is applicable. Bear in mind, the quote is from the NICHD, not the NIH directly, but NICHD does fall under the NIH umbrella.
Message in reply to:
Endorsed? This is simply not accurate and not the position the NIH took. Some of their words...
"may be a promising"
"we are hopeful"
"clinical studies are needed to determine if the drug is effective in patients, particularly early in the disease course when the virus begins to replicate"
Saying that the NIH "endorsed" is misleading!
Recent ADMP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:50:07 PM
- Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus • GlobeNewswire Inc. • 09/07/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:45:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2023 09:20:33 PM
- Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/21/2023 01:15:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:38:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 08/10/2023 08:03:30 PM
- Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering • GlobeNewswire Inc. • 08/04/2023 05:43:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:59:45 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/03/2023 08:55:39 PM
- Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering • GlobeNewswire Inc. • 08/02/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2023 04:15:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2023 09:01:12 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/28/2023 08:58:05 PM
- Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert • GlobeNewswire Inc. • 07/28/2023 12:30:00 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 07/27/2023 10:08:01 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/27/2023 01:17:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:20:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:15:12 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/13/2023 08:37:24 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM